CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins (“HP-ß-CD”) is indicated for the treatment of meibomian gland dysfunction (“MGD”) associated dry eye disease (“DED”).  MGD is the leading cause of DED, contributing to 70-86% of all DED cases globally. It is characterized by terminal duct obstruction along with qualitative or quantitative changes in glandular secretions which cause tear film abnormalities that lead to evaporative DED. Symptoms of MGD include ocular surface irritation, inflammation, and ocular surface disease which, if left untreated, can lead to visual disruption. MGD also commonly occurs with an eyelid problem called blepharitis, which causes inflamed eyelids and a crusty discharge at the base of the eyelashes. High risk groups of MGD include the female population and in the elderly population.

CBT-006 is in the form of eye drops with a novel mechanism of action of sequestration of excess cholesterol at the meibomian gland orifice and in the meibum, to improve meibum secretion. We believe this mechanism can improve tear film quality and meibum mobility in patients with MGD and DED, thus relieving signs and symptoms associated with MGD and DED.